Suresh Ramalingam, MD

Suresh Ramalingam, MD






Suresh Ramalingam, MD, Professor, Chief of Thoracic Oncology and Director of Medical Oncology, started practicing at Emory in 2007.




Specialties

  • Medical Oncology (Board certified since 2003)

Areas of Expertise

  • Hematology/oncology
  • Lung cancer
  • Mesothelioma
  • Other thoracic cancers

Groundbreaking Research and Clinical Trials

Dr. Ramalingam specializes in the treatment of lung cancer and leads a group of physicians, scientists and care providers at Emory, whose collective goals and aspirations are to improve the outcomes for every patient with lung cancer. Emory has a world-class multi-disciplinary team for the treatment of lung cancer that sets it apart from most other centers. Their goal is to provide innovative treatment options, either as standard or as part of research studies, to every patient with lung cancer.

Dr. Ramalingam’s own research focus has been to develop new drugs for the treatment of lung cancer. He also has a special interest in the management of elderly patients. He has a strong interest in the conduct of early phase clinical trials with novel translational endpoints to identify molecular effects of the experimental agents at the tumor level. His recent work has focused on the use of histone deacetylase inhibitors in the treatment of advanced non-small cell lung cancer, in combination with standard chemotherapy. Other novel agents of interest and under active investigation by his group include inhibitors of vascular endothelial growth factor receptor, PARP inhibitors, second generation EGFR inhibitors and heat shock protein inhibitors. All of these clinical trials include biomarker studies that will help towards individualized therapy for patients with lung cancer.

Dr. Ramalingam serves as the co-chair of the Lung Cancer Working Group of the Georgia Cancer Coalition, with the goal of conducting clinical trials across the state of Georgia. He is also the co-chair of the Thoracic Committee of the Eastern Cooperative Oncology Group, a national organization involved in the development of new standards of care for the treatment of cancer. Through these roles, he interacts closely with researchers, physicians, patient advocates and policy experts that are instrumental in helping to build a premier lung cancer program at Emory.

The Road to Emory: Education

  • Medical School: Kilpauk Medical College, Tamil Nadu, India, 1992
  • Internship: Wayne State University, Detroit, MI, 1994
  • Residency: Wayne State University, Detroit, MI, 1996
  • Fellowship: University of Pittsburgh Medical Center, Pittsburgh, PA, 2003

Memberships

  • American Association for Cancer Research
  • American Society of Clinical Oncology
  • Eastern Cooperative Oncology Group
  • International Association for Study of Lung Cancer

Awards

  • James Eckman Award for Excellence in Teaching, Emory University, June 2008
  • Clinical Research Career Development Award - American Society of Clinical Oncology, June 2006
  • Paul Ruble ‘Teacher of the Year’ Award, Wayne State University, June 2000
  • UPCI Leadership Award for clinical trials program development University of Pittsburgh, May 2005

Major or Recent Publications

  • Lung Cancer in Elderly Patients: An Analysis of the SEER Database. Journal of Clinical Oncology, December 2007, N/A.
  • Outcomes for Elderly Advanced Stage Non-small Cell Lung Cancer Patients Treated with Bevacizumab in Combination with Carboplatin and Paclitaxel: Analysis of the ECOG 4599 Study. Journal of Clinical Oncology, January 2008, N/A.
  • Phase I and pharmacokinetic study of Vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clinical Cancer Research, June 2006,3605-10.

Personal

Dr. Ramalingam’s hobbies include reading, listening to music, watching movies and spending time with his family. “Our 4-year old son keeps us on our toes,” he says. “With him, it feels like we have a second pair of eyes to look at daily events and the world.”